Latest

09:53
[ Samsung S&P Gsci Crude Oil Er Futures Etf (03175.HK) Rises 1.46% in Morning Trade, AUM at HKD 304 Million ] As of September 7 at 09:51, Samsung S&P Gsci Crude Oil Er Futures Etf (03175.HK) rose 1.46%, with a latest price of HKD 11.140.
Tag： Samsung S&P Gsci Crude Oil Er Futures EtfETF03175.HK
09:46
[ Ishares Core Msci Taiwan Index Etf (03074.HK) Rises 1.53% in Morning Trade, Latest NAV at HKD 492.734 ] As of September 7 at 09:47, Ishares Core Msci Taiwan Index Etf (03074.HK) rose 1.53%, with a latest price of HKD 504.600.
Tag： Ishares Core Msci Taiwan Index Etf03074.HKETF
09:44
[ ETF Financing Ranking | Harvest SSE STAR Chip ETF (588200) had a net financing buy-in of CNY 101.62 million ] Sep 4, 2026, Harvest SSE STAR Chip ETF (588200.SH) had a net financing buy-in of CNY 101.62 million.
Tag： Harvest SSE STAR Chip ETF588200.SHNewTimeSpace
09:44
[ ETF Financing Ranking | GF Fund SSE Science and Technology Innovation Board 50 ETF (588060) had a net financing buy-in of CNY 16.3 million ] Sep 4, 2026, GF Fund SSE Science and Technology Innovation Board 50 ETF (588060.SH) had a net financing buy-in of CNY 16.3 million.
Tag： GF Fund SSE Science and Technology Innovation Board 50 ETF588060.SHNewTimeSpace
09:44
[ ETF Financing Ranking | China Southern CSI 1000 ETF (512100) had a net financing buy-in of CNY 23.24 million ] Sep 4, 2026, China Southern CSI 1000 ETF (512100.SH) had a net financing buy-in of CNY 23.24 million.
Tag： China Southern CSI 1000 ETF512100.SHNewTimeSpace
09:44
[ ETF Financing Ranking | China Southern CSI 500 ETF (510500) had a net financing buy-in of CNY 151.01 million ] Sep 4, 2026, China Southern CSI 500 ETF (510500.SH) had a net financing buy-in of CNY 151.01 million
Tag： China Southern CSI 500 ETF510500.SHNewTimeSpace
09:44
[ ETF Financing Ranking | Hwabao WP CSI Banks ETF (512800) had a net financing buy-in of CNY 77.75 million ] Sep 4, 2026, Hwabao WP CSI Banks ETF (512800.SH) had a net financing buy-in of CNY 77.75 million.
Tag： Hwabao WP CSI Banks ETF512800.SHNewTimeSpace
09:44
[ ETF Financing Ranking | Fullgoal SSE Composite ETF (510210) had a net financing buy-in of CNY 39.84 million ] Sep 4, 2026, Fullgoal SSE Composite ETF (510210.SH) had a net financing buy-in of CNY 39.84 million.
Tag： Fullgoal SSE Composite ETF510210.SHNewTimeSpace
09:40
[ Bosera Szse Chinext Daily (2x) Leveraged Product (07234.HK) Rises 2.22% in Morning Trade, Latest Price at HKD 8.530 ] As of September 7 at 09:41, Bosera Szse Chinext Daily (2x) Leveraged Product (07234.HK) rose 2.22%, with a latest price of HKD 8.530.
Tag： 07234.HKETFBosera Szse Chinext Daily (2x) Leveraged Product
08:36
[ HBM HOLDINGS-B (02142.HK): Shares Added to Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Lists, Effective 7 September 2026 ] On 7 September 2026, HBM HOLDINGS-B (02142.HK) announced that its shares have been added to the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect lists, effective 7 September 2026, enabling direct investment by qualified mainland Chinese investors through the Stock Connect mechanism.
Tag： HBM HOLDINGS-B02142.HK
08:21
[ TENNOR THERAP-B (06872.HK): Positive Phase IIa Proof-of-Concept Data for Rifaquizalone (TNP-2092) in Prosthetic Joint Infection; Multicenter Phase IIb Initiated ] On 7 September 2026, TENNOR THERAP-B (06872.HK) reported positive Phase IIa proof-of-concept data for rifaquizalone (TNP-2092) in prosthetic joint infection. Based on these data, a multicenter Phase IIb trial has been approved by the NMPA and recently initiated.
Tag： TENNOR THERAP-B06872.HKR&D Progress
08:16
[ CSTONE PHARMA-B (02616.HK): Shares Added to Stock Connect Eligible List, Effective 7 September 2026 ] On 7 September 2026, CSTONE PHARMA-B (02616.HK) announced that its shares have been added to the Stock Connect eligible list, effective 7 September 2026. CEO Dr. Yang Jianxin stated that the inclusion is expected to broaden the investor base and enhance liquidity. Core asset CS2009 trispecific antibody is advancing in global Phase I/II, with the first global Phase III registrational trial expected to start before end-2026.
Tag： CSTONE PHARMA-B02616.HKStock Connect
08:07
[ FOSUN PHARMA (02196.HK): Sells 6% Stake in India's Gland Pharma for Approximate USD 294 Million ] On 6 September 2026, FOSUN PHARMA (02196.HK) announced that its subsidiary Fosun Pharma Singapore sold 9.897 million shares (6.00%) of India's Gland Pharma on 4 September 2026 for approximately USD 294 million, at a 2.72% discount to the previous closing price. Post-transaction, the group's stake falls to approximately 45.76% while it remains the controlling shareholder; proceeds are designated for R&D investment, share buybacks and debt repayment, with settlement expected on 7 September 2026 India time.
Tag： FOSUN PHARMA02196.HKEquity Disposal
08:03
[ PICC GROUP (01339.HK): Nominates Ms. Yang Dongning as Candidate for Executive Director of the Fifth Session of the Board ] On 6 September 2026, PICC GROUP (01339.HK) approved the nomination of Ms. Yang Dongning as a candidate for executive director of the fifth session of the Board.
Tag： PICC GROUP01339.HK
08:00
[ KEYMED BIO-B (02162.HK): Non-Executive Director Dr. Wang Minchuan Resigns, Effective 4 September 2026 ] On 6 September 2026, KEYMED BIO-B (02162.HK) announced that Dr. Wang Minchuan has resigned as a non-executive director, effective 4 September 2026, to focus on other commitments, confirming no disagreement with the Board and no matters requiring shareholder or exchange attention.
Tag： KEYMED BIO-B02162.HK
07:49
[ KINTOR PHARMA-B (09939.HK): Long-Term Safety Trial of KT-939 Completed; No Skin Adverse Reactions in 114 Subjects Over 52 Weeks ] On 7 September 2026, KINTOR PHARMA-B (09939.HK) announced the completion of the long-term safety trial of KT-939, a novel tyrosinase inhibitor, on 4 September 2026, with no skin adverse reactions observed among 114 subjects after 52 weeks of continuous use of 0.2% KT-939.
Tag： KINTOR PHARMA-B09939.HKR&D Progress
07:45
[ RIVERINE CHINA (01417.HK): Public Float Falls to 23.85%, Below the 25% Minimum; Restoration Expected Within 6 Months ] On 7 September 2026, RIVERINE CHINA (01417.HK) announced that its public float stood at approximately 23.85%, below the 25% minimum required by the Listing Rules, after 8,218,000 shares (approximately 2.03% of issued share capital) held by the share award scheme trustee were excluded from the public float. The company is considering options including trustee share sales and/or a new share issuance to the public, and expects to restore the public float within 6 months.
Tag： RIVERINE CHINA01417.HKPublic Float
07:39
[ CLOVER BIO-B (02197.HK): Positive Phase II Data for Respiratory Combo Vaccine Candidates in Australian Elderly ] On 7 September 2026, CLOVER BIO-B (02197.HK) reported positive Phase II data for respiratory combination vaccine candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) among 420 elderly subjects in Australia.
Tag： CLOVER BIO-B02197.HKR&D Progress
07:32
[ WANGUO GOLD GP (03939.HK): Subscribes USD 103.8 Million to JPMorgan Mansart Overnight Fund ] On 7 September 2026, WANGUO GOLD GP (03939.HK) announced a subscription of USD 103,834,600 in the JPMorgan Mansart Overnight Fund on 4 September 2026, constituting a discloseable transaction.
Tag： WANGUO GOLD GP03939.HKCash Management
20:58
[ HK Connect Weekly: HSTECH falls 0.77% for the week as Hang Seng Index quarterly review takes effect and Baidu completes dual primary listing - 20260904 ] During the week (31 August to 4 September), Hong Kong equities diverged: the HSI rose 0.26%, the Hang Seng TECH Index fell 0.77% and the HSCEI rose 0.76%, with net southbound inflows of about HK$ 7.363 billion for the full week. The HSI quarterly review took effect, adding Hua Hong Grace and Weichai Power, while Iluvatar CoreX joined the HSTECH; Goldman Sachs expects USD 870 million of passive inflows into tech hardware and semiconductors. The MSCI China Index review took effect, adding Z.AI and Kingboard Holdings. Baidu completed its dual primary listing and could join Stock Connect as early as 7 September. The AI application sector led gains on OpenAI's GPT-6 Astra release, with PHANCY up nearly 15%; HUTCHMED's major licensing deal with GSK triggered a breakout in innovative drug names. Semiconductors diverged sharply, with Hua Hong Grace tumbling 8.43% despite its HSI inclusion.
Tag： HK Connect WeeklyHUA HONG GRACEWEICHAI POWER
Previous1..7677 787980..576     576 pages total
×
Share to WeChat

Open WeChat, use "Scan," and share to my Moments